



Diabetes Presentation in Infancy: High Risk of Diabetic Ketoacidosis

Diabetes Care 2017;40:e147–e148 | <https://doi.org/10.2337/dc17-1145>

Lisa R. Letourneau,¹ David Carmody,²
Kristen Wroblewski,³
Anna M. Denson,¹ May Sanyoura,¹
Rochelle N. Naylor,^{1,4}
Louis H. Philipson,¹ and
Siri Atma W. Greeley^{1,4}

Diabetes in childhood has been associated with increased morbidity and mortality, but the risks for diabetes in infancy remain unclear. Cases with onset of hyperglycemia in the first 6 months of life consist predominantly of monogenic diabetes, whereas type 1 autoimmune diabetes accounts for the majority of cases beyond this threshold. Regardless of etiology, diabetes symptoms tend to be difficult to recognize in an infant, putting patients at increased risk for delays in diagnosis, which may lead to higher blood glucose levels and diabetic ketoacidosis (DKA) at presentation. Here, we report a high degree of morbidity among a cohort of subjects with infancy-onset diabetes.

We examined diagnosis records from 88 cases with diabetes onset ≤ 13 months of age collected through the University of Chicago Monogenic Diabetes Registry (1). We assessed laboratory values and sign/symptoms, and if a causal mutation for diabetes was detected, participants were subdivided by similar mutation subtypes. Data were managed using REDCap electronic data capture tools and analyzed using Stata version 14 (StataCorp, 2015).

The majority of participants were male ($n = 46, 52\%$), Caucasian ($n = 55, 63\%$), and living in the United States ($n = 83, 94\%$). There was no significant difference across

mutation subtypes based on socioeconomic status ($P = 0.19$), race/ethnicity ($P = 0.36$), or sex ($P = 0.07$). *KCNJ11*-related diabetes was the most common form of infancy-onset diabetes (37.5%, $n = 33$), followed by “Unknown” (likely type 1 diabetes) (21.6%, $n = 19$); 14% ($n = 12$) had transient neonatal diabetes. Median age at diabetes diagnosis was 10.4 weeks and was significantly different by mutation subtype (Table 1). When grouped into permanent versus transient diabetes, diagnosis age was significantly lower in the transient group (median 15.2 weeks vs. 0.43 weeks, $P < 0.001$). The most commonly reported signs/symptoms were polyuria ($n = 32$), tachypnea ($n = 31$), flu-like symptoms ($n = 30$), tiredness/weakness ($n = 28$), dehydration ($n = 27$), and “not acting right” ($n = 26$). Blood glucose, pH, bicarbonate, HbA_{1c}, and DKA were dependent on mutation subtype (Table 1). Overall frequency of DKA was 66.2% (Table 1), and odds of DKA increased with age at diagnosis (odds ratio per 1 month increase 1.23 [95% CI 1.04, 1.45]).

In this study—the largest of its kind—DKA was more frequent than in other early-onset U.S. studies (2,3) or other cohorts of patients with neonatal diabetes (4,5). One reason for this may be a delay in diagnosis, which is reflected in the increased likelihood of DKA at a later

age of diagnosis found in our study. This delay may be related to the challenge of diagnosing diabetes in infants who cannot communicate symptoms and in whom polydipsia and polyuria may not be readily apparent and could even be reassuring to clinicians. Presentation characteristics were different by mutation subtype, therefore this information (in addition to genetic testing) may help to guide providers when making clinical decisions. Continuing to educate pediatric providers about the many ways that infants can present with diabetes may help to diagnose cases more efficiently and ultimately decrease the frequency of DKA at diagnosis. Further study is needed to develop effective strategies to reduce morbidity and mortality in this vulnerable population.

Acknowledgments. The authors would like to recognize the student research assistants who contributed to data entry on this project: Janu Arun (Chicago Medical School, Rosalind Franklin University), Ade Ayoola (University of Chicago), Monica Lanning (University of Chicago), Maddie McLaughlin (Purdue University), Kiran Munir (Chicago Medical School, Rosalind Franklin University), Sai Talluru (Johns Hopkins University), and Kandace Williamson (University of Chicago). The authors thank all the clinicians providing care for patients within the Monogenic Diabetes Registry (<http://monogenicdiabetes.uchicago.edu>).

¹Section of Adult and Pediatric Endocrinology, Diabetes, and Metabolism, Department of Medicine, The University of Chicago, Chicago, IL

²Department of Endocrinology, Singapore General Hospital, Singapore

³Department of Public Health Sciences, The University of Chicago, Chicago, IL

⁴Section of Adult and Pediatric Endocrinology, Diabetes, and Metabolism, Department of Pediatrics, The University of Chicago, Chicago, IL

Corresponding author: Siri Atma W. Greeley, sgreeley@uchicago.edu.

Received 8 June 2017 and accepted 19 July 2017.

© 2017 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <http://www.diabetesjournals.org/content/license>.

Table 1—Details of diabetes diagnosis by mutation subtype

	KCNJ11/ABCC8*	INS/EIF2AK3*	6q24*	FOXP3/IL2RA*	GATA6/PDX1*	Unknown (likely T1D)*	Total*	P value
Number of participants, n (%)	41 (46.6)	13 (14.8)	10 (11.4)	3 (3.4)	2 (2.3)	19 (21.6)	88 (100)	
Current age, years	9.5 (5.2–14)	5.3 (2.5–8.6)	3.7 (1.4–5.4)	3.3 (3.2–6.6)	3.2 (2.2–4.2)	10.9 (6.7–17.9)	7.7 (4.1–14.0)	
Age at diagnosis, weeks	9.6 (6.1–18.3)	10 (6.1–17.4)	0.4 (0–0.9)	14.8 (0–22.2)	9.1 (0–18.3)	42.6 (37.4–50.4)	10.4 (5.2–26.5)	<0.001†
Glucose, mg/dL‡	716.5 (563–870)	435 (319–625)	408 (300–502)	920 (342–1,600)	411 (355–467)	736 (526–840)	618 (477–800)	<0.001†
pH§	7.07 (6.87–7.26)	7.41 (7.4–7.43)	7.43 (7.39–7.46)	6.95 (6.9–7.0)	7.11 (6.9–7.31)	7.08 (7.0–7.27)	7.08 (6.98–7.31)	0.02†
Bicarbonate, mmol/L	6.0 (4.6–11.0)	16.4 (15.0–25.0)	21.1 (20.0–21.8)	13.0 (6.0–20.0)	16.0 (7.0–25.0)	5.0 (4.0–10.4)	7.0 (5.0–18.8)	0.005†
HbA _{1c} % [mmol/mol]¶	12.0 [108] (9.3–13.6) ([78–125])	9.9 [85] (8.5–10.9) ([69–96])	NA	4.9 [30]	NA	8.8 [73] (6.9–9.8) ([52–84])	9.9 [85] (8.3–12.2) ([67–110])	0.04†
DKA, n (%)#	26 (78.8)	3 (30)	0 (0)	3 (100)	1 (50)	14 (87.5)	47 (66.2)	<0.001†

All data presented as median (interquartile range) unless otherwise specified. T1D, type 1 diabetes; NA, not available. *In most cases, the mutation subtype was not reported in the medical record but rather was available for each case through the Monogenic Diabetes Registry data. Mutation subtypes were grouped according to functional similarities. All participants in the “Unknown” category did not have an identifiable monogenic cause of diabetes at the time of data analysis. Some of these participants had positive diabetes autoantibodies, and thus likely had autoimmune type 1 diabetes. †Statistically significant by Wilcoxon rank sum test, Kruskal-Wallis test, or Fisher exact test. ‡Because of limited sample sizes, pairwise comparisons were not performed. †Data available from 73 participants. §Data available from 49 participants. ¶Data available from 58 participants. #Data available from 27 participants; HbA_{1c} < 6 months are underestimated owing to fetal hemoglobin. †Data available from 71 participants.

They are most grateful to all of the patients and families who participated in this study.

Funding. This work was supported by an investigator-initiated grant from Novo Nordisk; grants from the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases (R01DK104942, DRTC P30DK020595, and K23DK094866 [to S.A.W.G.]), the National Institutes of Health National Center for Advancing Translational Sciences (CTSA UL1TR000430), and the American Diabetes Association (1-11-CT-41 and 1-17-JDF-008); and gifts from the Kovler Family Foundation.

Duality of Interest. No conflicts of interest relevant to this article were reported.

Author Contributions. L.R.L. wrote the manuscript and collected, analyzed, and interpreted data. D.C. contributed to study design and interpreted data. K.W. provided biostatistical analysis and interpreted data. A.M.D. conducted the literature review and collected, analyzed, and interpreted data. M.S. provided genetic testing support and interpreted data. R.N.N. contributed to study design and interpreted data. L.H.P. designed the study, provided administrative and material support, and obtained funding. S.A.W.G. designed the study; collected, analyzed, and interpreted data; provided administrative and material support; obtained funding; and supervised the study. All authors reviewed and edited the manuscript, contributed to discussion, and approved the final manuscript. S.A.W.G. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

References

- Greeley SAW, Naylor RN, Cook LS, Tucker SE, Lipton RB, Philipson LH. Creation of the Web-based University of Chicago Monogenic Diabetes Registry: using technology to facilitate longitudinal study of rare subtypes of diabetes. *J Diabetes Sci Technol* 2011;5:879–886
- Quinn M, Fleischman A, Rosner B, Nigrin DJ, Wolfsdorf JL. Characteristics at diagnosis of type 1 diabetes in children younger than 6 years. *J Pediatr* 2006;148:366–371
- Dabelea D, Rewers A, Stafford JM, et al.; SEARCH for Diabetes in Youth Study Group. Trends in the prevalence of ketoacidosis at diabetes diagnosis: the SEARCH for Diabetes in Youth study. *Pediatrics* 2014;133:e938–e945
- Pearson ER, Flechtner I, Njølstad PR, et al.; Neonatal Diabetes International Collaborative Group. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. *N Engl J Med* 2006;355:467–477
- Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. *N Engl J Med* 2004;1838–1849